Proteomics and Precise Exercise Phenotypes in Heart Failure With Preserved Ejection Fraction: A Pilot Study

Proteomics and Precise Exercise Phenotypes in Heart Failure With Preserved Ejection Fraction: A Pilot Study

Background While exercise impairments are central to symptoms and diagnosis of heart failure with preserved ejection fraction (HFpEF), prior studies of HFpEF biomarkers have mostly focused on resting phenotypes. We combined precise exercise phenotypes with cardiovascular proteomics to identify prote...

Bibliografski detalji
Glavni autori:	Ravi V. Shah, Shih‐Jen Hwang, Venkatesh L. Murthy, Shilin Zhao, Kahraman Tanriverdi, Priya Gajjar, Kevin Duarte, Mark Schoenike, Robyn Farrell, Liana C. Brooks, Deepa M. Gopal, Jennifer E. Ho, Nicholas Girerd, Ramachandran S. Vasan, Daniel Levy, Jane E. Freedman, Gregory D. Lewis, Matthew Nayor
Format:	Članak
Jezik:	English
Izdano:	Wiley 2023-11-01
Serija:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Teme:	biomarkers exercise hemodynamics HFpEF proteomics
Online pristup:	https://www.ahajournals.org/doi/10.1161/JAHA.122.029980

Slični predmeti

Right Ventricular‐Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction
od: Zheng‐Wei Chen, i dr.
Izdano: (2024-01-01)

The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
od: Becker Al-Khayatt, i dr.
Izdano: (2024-05-01)

Exploring the Noninvasive Evaluation of the Pulmonary Pressure–Flow Relationship During Exercise
od: Mads J. Andersen, i dr.
Izdano: (2024-08-01)

Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial
od: Kramer J. Wahlberg, i dr.
Izdano: (2024-01-01)

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
od: Elisabeth A. Jalink, i dr.
Izdano: (2024-01-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
od: Stephanie J. Rowe, BBiomed, MD, i dr.
Izdano: (2025-01-01)

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum
od: Karolina Andrzejczyk, i dr.
Izdano: (2024-06-01)

Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
od: Alberto Palazzuoli, i dr.
Izdano: (2023-01-01)

Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
od: José M. Inácio, i dr.
Izdano: (2023-07-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
od: Kyle B. LaPenna, i dr.
Izdano: (2021-03-01)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
od: Zhen Hui Peh, i dr.
Izdano: (2023-06-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
od: Mark Sweeney, i dr.
Izdano: (2020-09-01)

Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
od: Domenico D'Amario, i dr.
Izdano: (2024-08-01)

Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
od: Xiao Wang, i dr.
Izdano: (2024-11-01)

Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis
od: Shu Li, i dr.
Izdano: (2023-08-01)

Dantrolene improves left ventricular diastolic property in mineralcorticoid-salt-induced hypertensive rats
od: Junya Nawata, i dr.
Izdano: (2023-07-01)

D‐dimer and outcomes in hospitalized heart failure patients across the ejection fraction phenotypes
od: Liyan Huang, i dr.
Izdano: (2022-10-01)

Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies
od: You Deng, i dr.
Izdano: (2024-01-01)

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction
od: Christopher J. Charles, i dr.
Izdano: (2020-10-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
od: Jenni Huusko, i dr.
Izdano: (2020-06-01)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
od: Anita Pintér, i dr.
Izdano: (2022-02-01)

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
od: Natasha L. Patel‐Murray, i dr.
Izdano: (2024-07-01)

Age‐stratified profiles and outcomes of patients with heart failure with preserved ejection fraction
od: Shinsuke Yamanaka, i dr.
Izdano: (2024-08-01)

p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction
od: Xiaonan Chen, i dr.
Izdano: (2022-06-01)

Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension
od: Min Chen, i dr.
Izdano: (2024-12-01)

A higher mortality in men compared to women with heart failure in primary care and ejection fraction equal to or more than 40%
od: Björn Eriksson, i dr.
Izdano: (2024-12-01)

Heart failure outcomes by left ventricular ejection fraction in a contemporary region‐wide patient cohort
od: Johan Sundström, i dr.
Izdano: (2024-06-01)

Variation in clinical and patient‐reported outcomes among complex heart failure with preserved ejection fraction phenotypes
od: Kelsey M. Flint, i dr.
Izdano: (2020-06-01)

Haemodynamic validation of the three‐step HFA‐PEFF algorithm to diagnose heart failure with preserved ejection fraction
od: Ettore Lanzarone, i dr.
Izdano: (2023-08-01)

Predictive value of NT pro BNP for new‐onset atrial fibrillation in heart failure and preserved ejection fraction
od: Xiao Liu, i dr.
Izdano: (2024-12-01)

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
od: Kengo Ayabe, i dr.
Izdano: (2024-10-01)

Percent Predicted Peak Exercise Oxygen Pulse Provides Insights Into Ventricular-Vascular Response and Prognosticates HFpEF
od: Jason P. Li, MD, i dr.
Izdano: (2024-08-01)

Diagnostic and prognostic value of the HFA-PEFF score for heart failure with preserved ejection fraction: a systematic review and meta-analysis
od: Xinmei Li, i dr.
Izdano: (2024-07-01)

Phenotypic Trajectories From Acute to Stable Phase in Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT‐HFpEF Study
od: Yuki Matsuoka, i dr.
Izdano: (2025-02-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
od: Tomasz Urbanowicz, i dr.
Izdano: (2024-11-01)

Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno‐Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction
od: Yuji Shi, i dr.
Izdano: (2024-12-01)

Glycosphingolipids in Cardiovascular Disease: Insights from Molecular Mechanisms and Heart Failure Models
od: Sarah Huang, i dr.
Izdano: (2024-10-01)

Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP‐HF registry
od: Matteo Pagnesi, i dr.
Izdano: (2024-02-01)

Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction
od: Yoran Crum, i dr.
Izdano: (2024-06-01)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
od: Mikael Erhardsson, i dr.
Izdano: (2023-12-01)